Eisai Co., Ltd. Logo

Eisai Co., Ltd.

A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.

4523 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
文京区小石川4丁目6番10号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Eisai Co., Ltd. is a global, research-based pharmaceutical company founded in 1941. It is engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products, with a portfolio that includes prescription medicines and over-the-counter drugs. The company operates under its core "human health care" (hhc) philosophy, which prioritizes patients and their families to enhance the benefits provided by healthcare. A key corporate initiative involves improving access to medicines for people in developing and emerging countries, exemplified by its program to supply treatments for lymphatic filariasis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-04 07:00
Regulatory News Service
訂正報告書(大量保有報告書・変更報告書)
Japanese 46.9 KB
2025-06-19 09:25
Post-Annual General Meeting Information
臨時報告書
Japanese 31.9 KB
2025-06-13 04:30
Governance Information
内部統制報告書-第113期(2024/04/01-2025/03/31)
Japanese 25.1 KB
2025-06-13 04:29
Registration Form
確認書
Japanese 8.1 KB
2025-06-13 04:28
Annual Report
有価証券報告書-第113期(2024/04/01-2025/03/31)
Japanese 5.2 MB
2025-06-03 08:00
Major Shareholding Notification
変更報告書
Japanese 39.0 KB
2025-05-13 08:00
Major Shareholding Notification
大量保有報告書
Japanese 37.9 KB
2025-05-08 09:00
Regulatory News Service
公開買付報告書
Japanese 41.0 KB
2025-04-01 08:00
M&A Activity
訂正公開買付届出書
Japanese 177.2 KB
2025-03-17 06:00
M&A Activity
公開買付届出書
Japanese 348.4 KB
2025-03-12 07:06
Board/Management Information
臨時報告書
Japanese 21.8 KB
2024-12-11 02:14
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.2 KB
2024-11-15 02:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2024-11-08 06:17
Regulatory News Service
確認書
Japanese 8.0 KB
2024-11-08 06:16
Interim Report
半期報告書-第113期(2024/04/01-2025/03/31)
Japanese 268.5 KB

Automate Your Workflow. Get a real-time feed of all Eisai Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Eisai Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden CLBIO
Cosma Spolka Akcyjna Logo
Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.
Poland COS
COSMO Pharmaceuticals N.V. Logo
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
Netherlands COPN
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea 060590
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan 4894
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea 365270
Curevac Logo
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
Germany CVAC
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea 372320
Cyfuse Biomedical K.K. Logo Japan 4892

Talk to a Data Expert

Have a question? We'll get back to you promptly.